Korea Biotech ADA Pitch: Monthly GLP-1s and Next-Wave Obesity Technologies From Hanmi, D&D Pharmatech, and Onegene
While the ADA stage belonged to Lilly and Novo, Korea Biomedical Review covered the Korean biotechs that sidestepped the headline duel and pitched monthly GLP-1s and next-wave obesity technologies. Hanmi Pharmaceutical, D&D Pharmatech, and Onegene Biotechnology made the case for differentiated dosing intervals, novel-mechanism peptides, and Asia-Pacific market positioning. The pattern echoes Chinese entrants like Innovent (mazdutide), Hengrui (ribupatide, HRS-7535), and Sciwind, and reinforces a meeting-wide pattern: the obesity field is broadening into a global, multi-mechanism pipeline.